Mark G Frattini Selected Research

enasidenib

11/2021	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
1/2021	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
1/2021	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
4/2020	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
11/2019	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark G Frattini Research Topics

Disease

8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 11/2008
6	Neoplasms (Cancer) 10/2022 - 06/2009
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2020 - 01/2018
2	Neutropenia 11/2021 - 01/2018
1	Tumor Lysis Syndrome 03/2023
1	Nausea 03/2023
1	Pneumonia (Pneumonitis) 11/2021
1	Thrombocytopenia (Thrombopenia) 11/2021
1	Febrile Neutropenia 11/2021
1	Lymphopenia (Lymphocytopenia) 12/2018
1	Infertility (Sterility) 12/2018
1	Carcinogenesis 12/2018
1	Leukemia 01/2018
1	Infections 01/2018
1	Respiratory Insufficiency (Respiratory Failure) 01/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018
1	Sepsis (Septicemia) 01/2018
1	Philadelphia Chromosome 02/2014
1	Cytokine Release Syndrome 02/2014
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2014
1	Hypersensitivity (Allergy) 07/2010
1	Pathologic Complete Response 07/2010
1	Alzheimer Disease (Alzheimer's Disease) 06/2009

Drug/Important Bio-Agent (IBA)

5	enasidenibIBA 11/2021 - 11/2019
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 12/2018
2	Chimeric Antigen ReceptorsIBA 10/2022 - 02/2014
2	Azacitidine (5 Azacytidine)FDA Link 11/2021 - 01/2021
2	ivosidenibIBA 01/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 11/2019 - 01/2018
2	Phosphotransferases (Kinase)IBA 12/2018 - 12/2009
1	Alanine Transaminase (SGPT)IBA 03/2023
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2023
1	BilirubinIBA 03/2023
1	lintuzumabIBA 01/2022
1	EnzymesIBA 01/2021
1	isocitric acid (isocitrate)IBA 04/2020
1	Ribosomal DNA (rDNA)IBA 12/2018
1	Protein Isoforms (Isoforms)IBA 12/2018
1	alpha-hydroxyglutarateIBA 12/2018
1	Micafungin (FK463)FDA Link 01/2018
1	IpilimumabIBA 01/2018
1	venetoclaxIBA 01/2018
1	posaconazole FDA Link 01/2018
1	CytokinesIBA 02/2014
1	CD19 AntigensIBA 02/2014
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 02/2014
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2014
1	Protein Kinases (Protein Kinase)IBA 09/2011
1	Phosphates (Orthophosphate)IBA 09/2011
1	Adenosine Diphosphate (ADP)IBA 09/2011
1	Interferon-gamma (Interferon, gamma)IBA 07/2010
1	Protein Subunit VaccinesIBA 07/2010
1	Oncogene Proteins (Oncogene Protein)IBA 07/2010
1	Peptides (Polypeptides)IBA 07/2010
1	Peptide Hydrolases (Proteases)FDA Link 06/2009
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 06/2009

Therapy/Procedure

7	Therapeutics 01/2021 - 11/2008
4	Drug Therapy (Chemotherapy) 01/2021 - 10/2012
1	Hematopoietic Stem Cell Transplantation 01/2021